Chad J. Kolean - 17 Jan 2023 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Reporting relationship: Chief Financial Officer
Issuer ticker: CLRB
Reported as of: 17 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jan 2023, 17:33:02 UTC
Prior SEC filing: 15 Apr 2022
Next SEC filing: 12 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Christina Blakley, Attorney in-fact for Chad J. Kolean

Key filing fact

Chad J. Kolean filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 18 Jan 2023.

Key facts

This page summarizes Chad J. Kolean's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jan 2023, 17:33.

Change

Previous filing in this sequence was filed on 15 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLRB transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +104,000
Change %
Price: $0.000000
Shares after: 104,000
Date: 17 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 104,000
Exercise price: $1.68
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.